These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 33689574)

  • 1. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.
    Zhang W; Yin Q; Huang H; Lu J; Qin H; Chen S; Zhang W; Su X; Sun W; Dong Y; Li Q
    Front Oncol; 2021; 11():628456. PubMed ID: 33928024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
    Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
    Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
    Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
    Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.
    Panya A; Thepmalee C; Sawasdee N; Saengmuang S; Luangwattananun P; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115827. PubMed ID: 37939617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
    Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
    Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
    Front Immunol; 2020; 11():576603. PubMed ID: 33329543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application.
    Wang X; Dai Z; Lin X; Zou X; Wang R; Tasiheng Y; Yan Y; Ma M; Chen Y; Cheng H; Liu C; Yu X
    Cancer Lett; 2024 Apr; 588():216741. PubMed ID: 38395378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells.
    Schwarz S; Schmitz J; Löffler MW; Ghosh M; Rammensee HG; Olshvang E; Markel M; Mockel-Tenbrinck N; Dzionek A; Krake S; Arslan B; Kampe KD; Wendt A; Bauer P; Mullins CS; Schlosser A; Linnebacher M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.